A one-size-fits-all approach to heart failure therapies is unlikely to be beneficial, highlighting the need to understand specific phenotypes and target relevant pathways in patient subgroups.
3] The reasons for these unfavorable trends are complex. One issue gaining wide acceptance is that the one-sizefits-all approach to HF therapies is unlikely to be beneficial, especially when new therapies are given on top of comprehensive neurohormonal blockade. Thus, it is crucial for the development of novel therapies to better understand the various HF phenotypes and their pathophysiology and subsequently target relevant pathways in such subgroups of patients.
Georgiopoulou et al. (Fri,) conducted a review in Heart failure with left ventricular dysfunction and pulmonary hypertension. A one-size-fits-all approach to heart failure therapies is unlikely to be beneficial, highlighting the need to understand specific phenotypes and target relevant pathways in patient subgroups.